Therapeutic vaccines take center stage at Pfizer

When Pfizer R&D chief Martin MacKay addressed the recent JP Morgan conference, he left no doubt how interested the pharma giant is in new biotech therapies--particularly therapeutic vaccines. Analysts quickly pointed to Pfizer's licensing deal with Avant Immunotherapeutics' brain cancer vaccine as a case in point.

While Pfizer readies its axe to hack down some 800 jobs in its research operations, other therapeutic vaccine developers should pay heed to Pfizer's plans. With less work in R&D, Pfizer is likely to aggressively go after new licensing deals as well as outright acquisitions. And that should bolster values among the biotech companies that fit their new strategy.

Analysts say that Pfizer has to scramble fast. Its recent attempts to introduce new blockbusters have derailed and in 2011 the company will lose patent protection on Lipitor, a cholesterol therapy that provides a quarter of the pharma giant's $48 billion in revenue.

- read the Dow Jones report
- check out the story in the Wall Street Journal

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

With COVID vaccinations expected to start in the coming weeks, 2021 is shaping up to be quite a year for the companies with leading vaccines.

The U.K. became the first Western country to authorize a COVID-19 vaccine, making the Pfizer/BioNTech shot the first mRNA vaccine for widespread use.